Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Grifols, S.A. (GRFS) vs Scilex Holding Company (SCLX)

Grifols, S.A. and Scilex Holding Company are both Drug Manufacturers General companies. Grifols, S.A. is the larger, with a market value of $1.9B against $34.8M — 53.5× the size. Scilex Holding Company has negative trailing earnings, so its P/E is not meaningful; Grifols, S.A. trades at 8.1×. Grifols, S.A. grew revenue faster over the last twelve months: 16.0% against −28.6%. Grifols, S.A. has the higher net margin (5.54% vs −1,418.5%) and the higher return on invested capital (0.00% vs 0.00%). Across the 17 metrics below, Grifols, S.A. leads on 13 and Scilex Holding Company on 4.

Valuation

Metric GRFS SCLX Drug Manufacturers General median
P/E 8.14 n/m 24.72
P/S 0.58 1.07 3.35
P/B 0.54 n/m 5.00
Price to free cash flow 6.76 n/m 17.68
EV/EBITDA 7.80 n/m 13.91
EV/Sales 1.75 3.63 3.95
Earnings yield 12.29% (1,016.36%) 2.92%
Free cash flow yield 14.79% (52.87%) 4.42%

Profitability

Metric GRFS SCLX Drug Manufacturers General median
Gross margin 37.45% 55.50% 72.77%
Operating margin 16.43% (1,136.40%) 18.90%
Net margin 5.54% (1,418.45%) 8.27%
Free cash flow margin 0.00% (56.37%) 17.25%
Return on equity 0.00% 160.27% 6.97%
Return on assets 0.00% (265.83%) 2.76%
Return on invested capital 0.00% 0.00% 6.30%

Growth

Metric GRFS SCLX Drug Manufacturers General median
Revenue growth (TTM) 16.03% (28.55%) 6.79%
EPS growth (last fiscal year) 168.00% (408.32%) —
Revenue growth, 5-year CAGR 7.84% (0.69%) 3.98%
Net income growth, 5-year CAGR 15.29% 0.00% 0.42%

Health

Metric GRFS SCLX Drug Manufacturers General median
Debt to equity 1.17 (0.26) 0.63
Current ratio 2.37 0.07 1.32
Net debt to EBITDA 5.19 (0.27) 1.15

Dividend

Metric GRFS SCLX Drug Manufacturers General median
Dividend yield 0.15% — 3.57%
Payout ratio 0.00 0.00 0.53

Size

Metric GRFS SCLX Drug Manufacturers General median
Market cap 1.86b 34.75m 125.91b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack